Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Ubi-Wan

Financiado

Cerrado

The origin and impact of impaired ubiquitin signaling in the degeneration of neu...

The origin and impact of impaired ubiquitin signaling in the degeneration of neurons Neurodegenerative diseases share similar hallmarks such as protein aggregation, suggesting that impaired protein degradation may be a common denominator. The major cellular pathways mediating protein degradation are the Ubiquitin-... ver más

31/10/2029

TECHNION ISRAEL I...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-11-01

ERC-2023-ADG: ERC ADVANCED GRANTS Scope:Objectives

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

TECHNION ISRAEL INSTITUTE O...

Lider

Proyectos interesantes

SAF2010-21058

Medical Technol...

Applied Physics

109K€ Cerrado

MECHAGGRENAMICS

Medical Technol...

Applied Physics

100K€ Cerrado

BFU2016-80295-R

Medical Technol...

Applied Physics

157K€ Cerrado

SYNPT

Medical Technol...

Applied Physics

159K€ Cerrado

SAF2012-36079

Medical Technol...

Applied Physics

187K€ Cerrado

UbiGolD

Medical Technol...

Data Science

185K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 59 meses Fecha Inicio: 2024-11-01
Fecha Fin: 2029-10-31

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Neurodegenerative diseases share similar hallmarks such as protein aggregation, suggesting that impaired protein degradation may be a common denominator. The major cellular pathways mediating protein degradation are the Ubiquitin-proteasome system (UPS) and autophagy, both regulated by ubiquitin signaling. However, aside from specific mutations in familial neurodegeneration cases, an early cause for failing ubiquitin-dependent proteolysis remains unclear. This proposal will test our unconventional hypothesis that dysregulated ubiquitin signaling is an early event in mechanisms of neurodegeneration, linking together numerous disease hallmarks. Towards this goal, we present groundbreaking findings that a mutated UPS protein resulting from a non-heritable transcription frameshift and present in the brains of neurodegenerative patients, particularly Alzheimer's disease (AD), is sufficient to trigger disease hallmarks in 3-D human neuronal cultures. This unique set-up replicates the main pathological hallmarks of AD without relying on any of the known genetic causes or risk factors. Utilizing this novel model, we have identified a previously unknown enzyme active site in a key neuroprotective protein, which now allows us to study the role of ubiquitin signaling in disease pathology.Specifically, this proposal seeks to understand both the source of disease-related ubiquitin signaling deterioration and its impact on neurons, by:1)Studying the mechanisms that trigger disruption of ubiquitin signaling in neurons.2)Understanding the consequences of altered ubiquitin signaling in human neuronal models of AD.3)Searching for mechanisms of neuroprotection mediated by key enzymes of the UPS. The outcome will develop new models of neurodegeneration, improve methods to study ubiquitin signaling in neurons, and yield a mechanistic understanding of UPS components in neuronal health and disease. Furthermore, the results will pave the way for developing new treatment approaches.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores